ImmunoGen, Inc.

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, VRTX has a market cap of 100.7B. Regarding current trading prices, IMGN is priced at $31.24, while VRTX trades at $390.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas VRTX's P/E ratio is 27.96. In terms of profitability, IMGN's ROE is -1.43%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, IMGN is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check VRTX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, REGN has a market cap of 60.5B. Regarding current trading prices, IMGN is priced at $31.24, while REGN trades at $565.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas REGN's P/E ratio is 14.62. In terms of profitability, IMGN's ROE is -1.43%, compared to REGN's ROE of +0.15%. Regarding short-term risk, IMGN is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check REGN's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ALNY has a market cap of 58.8B. Regarding current trading prices, IMGN is priced at $31.24, while ALNY trades at $442.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ALNY's P/E ratio is -181.01. In terms of profitability, IMGN's ROE is -1.43%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, IMGN is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ALNY's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IMGN is priced at $31.24, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IMGN's ROE is -1.43%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IMGN and SGEN have similar daily volatility (0.10).Check SGEN's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ARGX has a market cap of 40B. Regarding current trading prices, IMGN is priced at $31.24, while ARGX trades at $652.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ARGX's P/E ratio is 33.29. In terms of profitability, IMGN's ROE is -1.43%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, IMGN is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ARGX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, BNTX has a market cap of 27.3B. Regarding current trading prices, IMGN is priced at $31.24, while BNTX trades at $112.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas BNTX's P/E ratio is -67.98. In terms of profitability, IMGN's ROE is -1.43%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, IMGN is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check BNTX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IMGN is priced at $31.24, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IMGN's ROE is -1.43%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, IMGN is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check BGNE's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, SMMT has a market cap of 19.8B. Regarding current trading prices, IMGN is priced at $31.24, while SMMT trades at $26.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas SMMT's P/E ratio is -26.43. In terms of profitability, IMGN's ROE is -1.43%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, IMGN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check SMMT's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IMGN is priced at $31.24, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IMGN's ROE is -1.43%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, IMGN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check DNA-WT's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, INCY has a market cap of 17B. Regarding current trading prices, IMGN is priced at $31.24, while INCY trades at $86.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas INCY's P/E ratio is 20.55. In terms of profitability, IMGN's ROE is -1.43%, compared to INCY's ROE of +0.34%. Regarding short-term risk, IMGN is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check INCY's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, RPRX has a market cap of 15.7B. Regarding current trading prices, IMGN is priced at $31.24, while RPRX trades at $36.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas RPRX's P/E ratio is 15.87. In terms of profitability, IMGN's ROE is -1.43%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, IMGN is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check RPRX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, GMAB has a market cap of 14.7B. Regarding current trading prices, IMGN is priced at $31.24, while GMAB trades at $22.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas GMAB's P/E ratio is 12.08. In terms of profitability, IMGN's ROE is -1.43%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, IMGN is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check GMAB's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, UTHR has a market cap of 14.2B. Regarding current trading prices, IMGN is priced at $31.24, while UTHR trades at $312.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas UTHR's P/E ratio is 12.22. In terms of profitability, IMGN's ROE is -1.43%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IMGN is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check UTHR's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IMGN is priced at $31.24, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IMGN's ROE is -1.43%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IMGN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check KRTX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ASND has a market cap of 12B. Regarding current trading prices, IMGN is priced at $31.24, while ASND trades at $192.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ASND's P/E ratio is -37.63. In terms of profitability, IMGN's ROE is -1.43%, compared to ASND's ROE of +1.91%. Regarding short-term risk, IMGN is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ASND's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, IMGN is priced at $31.24, while BMRN trades at $58.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas BMRN's P/E ratio is 16.97. In terms of profitability, IMGN's ROE is -1.43%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, IMGN is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check BMRN's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, MRNA has a market cap of 10.9B. Regarding current trading prices, IMGN is priced at $31.24, while MRNA trades at $26.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas MRNA's P/E ratio is -3.73. In terms of profitability, IMGN's ROE is -1.43%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, IMGN is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check MRNA's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, EXEL has a market cap of 10.3B. Regarding current trading prices, IMGN is priced at $31.24, while EXEL trades at $38.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas EXEL's P/E ratio is 18.42. In terms of profitability, IMGN's ROE is -1.43%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, IMGN is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check EXEL's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, BBIO has a market cap of 9.8B. Regarding current trading prices, IMGN is priced at $31.24, while BBIO trades at $51.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas BBIO's P/E ratio is -12.43. In terms of profitability, IMGN's ROE is -1.43%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, IMGN is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check BBIO's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IMGN is priced at $31.24, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IMGN's ROE is -1.43%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IMGN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check RXDX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, IMGN is priced at $31.24, while VRNA trades at $105.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas VRNA's P/E ratio is -101.22. In terms of profitability, IMGN's ROE is -1.43%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, IMGN is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check VRNA's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, TECH has a market cap of 8.4B. Regarding current trading prices, IMGN is priced at $31.24, while TECH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas TECH's P/E ratio is 116.52. In terms of profitability, IMGN's ROE is -1.43%, compared to TECH's ROE of +0.06%. Regarding short-term risk, IMGN is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check TECH's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IMGN is priced at $31.24, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IMGN's ROE is -1.43%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, IMGN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check BPMC's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, MDGL has a market cap of 8.2B. Regarding current trading prices, IMGN is priced at $31.24, while MDGL trades at $371.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas MDGL's P/E ratio is -29.21. In terms of profitability, IMGN's ROE is -1.43%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, IMGN is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check MDGL's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IMGN is priced at $31.24, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas CERE's P/E ratio is -16.47. In terms of profitability, IMGN's ROE is -1.43%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IMGN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check CERE's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ROIV has a market cap of 8.1B. Regarding current trading prices, IMGN is priced at $31.24, while ROIV trades at $11.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ROIV's P/E ratio is -10.87. In terms of profitability, IMGN's ROE is -1.43%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, IMGN is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ROIV's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, IMGN is priced at $31.24, while HALO trades at $65.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas HALO's P/E ratio is 15.39. In terms of profitability, IMGN's ROE is -1.43%, compared to HALO's ROE of +1.37%. Regarding short-term risk, IMGN is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check HALO's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, IMGN is priced at $31.24, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, IMGN's ROE is -1.43%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, IMGN is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ROIVW's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, IMGN is priced at $31.24, while CORT trades at $72.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas CORT's P/E ratio is 64.06. In terms of profitability, IMGN's ROE is -1.43%, compared to CORT's ROE of +0.20%. Regarding short-term risk, IMGN is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check CORT's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, JAZZ has a market cap of 7.1B. Regarding current trading prices, IMGN is priced at $31.24, while JAZZ trades at $116.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas JAZZ's P/E ratio is -16.87. In terms of profitability, IMGN's ROE is -1.43%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, IMGN is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check JAZZ's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, IONS has a market cap of 7B. Regarding current trading prices, IMGN is priced at $31.24, while IONS trades at $42.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas IONS's P/E ratio is -24.87. In terms of profitability, IMGN's ROE is -1.43%, compared to IONS's ROE of -0.45%. Regarding short-term risk, IMGN is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check IONS's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, RVMD has a market cap of 6.8B. Regarding current trading prices, IMGN is priced at $31.24, while RVMD trades at $36.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas RVMD's P/E ratio is -8.04. In terms of profitability, IMGN's ROE is -1.43%, compared to RVMD's ROE of -0.39%. Regarding short-term risk, IMGN is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check RVMD's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IMGN is priced at $31.24, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas RETA's P/E ratio is -66.29. In terms of profitability, IMGN's ROE is -1.43%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IMGN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check RETA's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, RYTM has a market cap of 6.5B. Regarding current trading prices, IMGN is priced at $31.24, while RYTM trades at $96.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas RYTM's P/E ratio is -32.43. In terms of profitability, IMGN's ROE is -1.43%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, IMGN is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check RYTM's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, RNA has a market cap of 6B. Regarding current trading prices, IMGN is priced at $31.24, while RNA trades at $46.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas RNA's P/E ratio is -13.05. In terms of profitability, IMGN's ROE is -1.43%, compared to RNA's ROE of -0.33%. Regarding short-term risk, IMGN is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check RNA's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IMGN is priced at $31.24, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IMGN's ROE is -1.43%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IMGN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check ABCM's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IMGN is priced at $31.24, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IMGN's ROE is -1.43%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IMGN is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ISEE's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, IMGN is priced at $31.24, while NUVL trades at $76.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas NUVL's P/E ratio is -15.46. In terms of profitability, IMGN's ROE is -1.43%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, IMGN is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check NUVL's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, AXSM has a market cap of 5.4B. Regarding current trading prices, IMGN is priced at $31.24, while AXSM trades at $108.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas AXSM's P/E ratio is -21.58. In terms of profitability, IMGN's ROE is -1.43%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, IMGN is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check AXSM's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, IMGN is priced at $31.24, while CRSP trades at $58.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas CRSP's P/E ratio is -11.06. In terms of profitability, IMGN's ROE is -1.43%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, IMGN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check CRSP's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ABVX has a market cap of 5.3B. Regarding current trading prices, IMGN is priced at $31.24, while ABVX trades at $69.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ABVX's P/E ratio is -20.60. In terms of profitability, IMGN's ROE is -1.43%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, IMGN is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ABVX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, MRUS has a market cap of 5.1B. Regarding current trading prices, IMGN is priced at $31.24, while MRUS trades at $66.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas MRUS's P/E ratio is -12.05. In terms of profitability, IMGN's ROE is -1.43%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, IMGN is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check MRUS's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, IMGN is priced at $31.24, while ALKS trades at $28.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ALKS's P/E ratio is 14.03. In terms of profitability, IMGN's ROE is -1.43%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, IMGN is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ALKS's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, CYTK has a market cap of 4.6B. Regarding current trading prices, IMGN is priced at $31.24, while CYTK trades at $38.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas CYTK's P/E ratio is -7.55. In terms of profitability, IMGN's ROE is -1.43%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, IMGN is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check CYTK's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, VKTX has a market cap of 4.5B. Regarding current trading prices, IMGN is priced at $31.24, while VKTX trades at $40.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas VKTX's P/E ratio is -25.99. In terms of profitability, IMGN's ROE is -1.43%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, IMGN is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check VKTX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IMGN is priced at $31.24, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IMGN's ROE is -1.43%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IMGN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check ALPN's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, TGTX has a market cap of 4.5B. Regarding current trading prices, IMGN is priced at $31.24, while TGTX trades at $27.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas TGTX's P/E ratio is 73.89. In terms of profitability, IMGN's ROE is -1.43%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, IMGN is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check TGTX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, IMGN is priced at $31.24, while KRYS trades at $150.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas KRYS's P/E ratio is 30.60. In terms of profitability, IMGN's ROE is -1.43%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, IMGN is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check KRYS's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, IMGN is priced at $31.24, while ACAD trades at $24.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ACAD's P/E ratio is 19.05. In terms of profitability, IMGN's ROE is -1.43%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, IMGN is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ACAD's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, IMGN is priced at $31.24, while PCVX trades at $31.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas PCVX's P/E ratio is -7.96. In terms of profitability, IMGN's ROE is -1.43%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, IMGN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check PCVX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IMGN is priced at $31.24, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas OPT's P/E ratio is -1.52. In terms of profitability, IMGN's ROE is -1.43%, compared to OPT's ROE of +2.60%. Regarding short-term risk, IMGN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check OPT's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, AAPG has a market cap of 4.1B. Regarding current trading prices, IMGN is priced at $31.24, while AAPG trades at $42.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas AAPG's P/E ratio is -60.54. In terms of profitability, IMGN's ROE is -1.43%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, IMGN is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check AAPG's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IMGN is priced at $31.24, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IMGN's ROE is -1.43%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IMGN is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check MRTX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ACLX has a market cap of 4.1B. Regarding current trading prices, IMGN is priced at $31.24, while ACLX trades at $71.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ACLX's P/E ratio is -21.67. In terms of profitability, IMGN's ROE is -1.43%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, IMGN is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ACLX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, IMGN is priced at $31.24, while ADMA trades at $16.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ADMA's P/E ratio is 19.99. In terms of profitability, IMGN's ROE is -1.43%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, IMGN is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ADMA's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, IMGN is priced at $31.24, while AKRO trades at $50.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas AKRO's P/E ratio is -12.96. In terms of profitability, IMGN's ROE is -1.43%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, IMGN is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check AKRO's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ZLAB has a market cap of 3.9B. Regarding current trading prices, IMGN is priced at $31.24, while ZLAB trades at $34.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ZLAB's P/E ratio is -17.86. In terms of profitability, IMGN's ROE is -1.43%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, IMGN is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ZLAB's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, TLX has a market cap of 3.9B. Regarding current trading prices, IMGN is priced at $31.24, while TLX trades at $10.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas TLX's P/E ratio is 128.22. In terms of profitability, IMGN's ROE is -1.43%, compared to TLX's ROE of +0.10%. Regarding short-term risk, IMGN is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check TLX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, IMGN is priced at $31.24, while PTCT trades at $48.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas PTCT's P/E ratio is 6.92. In terms of profitability, IMGN's ROE is -1.43%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, IMGN is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check PTCT's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, SLNO has a market cap of 3.8B. Regarding current trading prices, IMGN is priced at $31.24, while SLNO trades at $77.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas SLNO's P/E ratio is -16.97. In terms of profitability, IMGN's ROE is -1.43%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, IMGN is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check SLNO's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IMGN is priced at $31.24, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IMGN's ROE is -1.43%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IMGN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check RYZB's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IMGN is priced at $31.24, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IMGN's ROE is -1.43%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IMGN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check CBAY's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IMGN is priced at $31.24, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IMGN's ROE is -1.43%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, IMGN is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check SWTX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, APLS has a market cap of 3.5B. Regarding current trading prices, IMGN is priced at $31.24, while APLS trades at $27.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas APLS's P/E ratio is -15.16. In terms of profitability, IMGN's ROE is -1.43%, compared to APLS's ROE of -1.16%. Regarding short-term risk, IMGN is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check APLS's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, IMGN is priced at $31.24, while PTGX trades at $54.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas PTGX's P/E ratio is 76.81. In terms of profitability, IMGN's ROE is -1.43%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, IMGN is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check PTGX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, IMGN is priced at $31.24, while MLTX trades at $54.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas MLTX's P/E ratio is -19.49. In terms of profitability, IMGN's ROE is -1.43%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, IMGN is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check MLTX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, IMGN is priced at $31.24, while LEGN trades at $37.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas LEGN's P/E ratio is -21.07. In terms of profitability, IMGN's ROE is -1.43%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, IMGN is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check LEGN's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, MIRM has a market cap of 3.4B. Regarding current trading prices, IMGN is priced at $31.24, while MIRM trades at $64.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas MIRM's P/E ratio is -56.14. In terms of profitability, IMGN's ROE is -1.43%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, IMGN is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check MIRM's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, MTSR has a market cap of 3.3B. Regarding current trading prices, IMGN is priced at $31.24, while MTSR trades at $30.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas MTSR's P/E ratio is -10.59. In terms of profitability, IMGN's ROE is -1.43%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, IMGN is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check MTSR's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, IMGN is priced at $31.24, while KYMR trades at $41.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas KYMR's P/E ratio is -12.21. In terms of profitability, IMGN's ROE is -1.43%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, IMGN is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check KYMR's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, SRRK has a market cap of 3B. Regarding current trading prices, IMGN is priced at $31.24, while SRRK trades at $32.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas SRRK's P/E ratio is -10.76. In terms of profitability, IMGN's ROE is -1.43%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, IMGN is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check SRRK's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, LGND has a market cap of 3B. Regarding current trading prices, IMGN is priced at $31.24, while LGND trades at $153.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas LGND's P/E ratio is -37.40. In terms of profitability, IMGN's ROE is -1.43%, compared to LGND's ROE of -0.09%. Regarding short-term risk, IMGN is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check LGND's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, XENE has a market cap of 2.9B. Regarding current trading prices, IMGN is priced at $31.24, while XENE trades at $37.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas XENE's P/E ratio is -10.77. In terms of profitability, IMGN's ROE is -1.43%, compared to XENE's ROE of -0.32%. Regarding short-term risk, IMGN is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check XENE's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, IMGN is priced at $31.24, while CRNX trades at $29.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas CRNX's P/E ratio is -7.49. In terms of profitability, IMGN's ROE is -1.43%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, IMGN is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check CRNX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, IMGN is priced at $31.24, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas MORF's P/E ratio is -14.88. In terms of profitability, IMGN's ROE is -1.43%, compared to MORF's ROE of -0.16%. Regarding short-term risk, IMGN is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check MORF's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, RARE has a market cap of 2.9B. Regarding current trading prices, IMGN is priced at $31.24, while RARE trades at $29.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas RARE's P/E ratio is -5.42. In terms of profitability, IMGN's ROE is -1.43%, compared to RARE's ROE of -2.37%. Regarding short-term risk, IMGN is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check RARE's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, IMGN is priced at $31.24, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas MOR's P/E ratio is -12.64. In terms of profitability, IMGN's ROE is -1.43%, compared to MOR's ROE of -1.84%. Regarding short-term risk, IMGN is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check MOR's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, ARWR has a market cap of 2.8B. Regarding current trading prices, IMGN is priced at $31.24, while ARWR trades at $18.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas ARWR's P/E ratio is -17.09. In terms of profitability, IMGN's ROE is -1.43%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, IMGN is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check ARWR's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, IMGN is priced at $31.24, while NAMS trades at $25.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas NAMS's P/E ratio is -15.77. In terms of profitability, IMGN's ROE is -1.43%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, IMGN is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check NAMS's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, IMGN is priced at $31.24, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas KDNY's P/E ratio is -12.47. In terms of profitability, IMGN's ROE is -1.43%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, IMGN is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check KDNY's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, IMGN is priced at $31.24, while IMVT trades at $15.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas IMVT's P/E ratio is -5.36. In terms of profitability, IMGN's ROE is -1.43%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, IMGN is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check IMVT's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, IMGN is priced at $31.24, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas MYOV's P/E ratio is -14.05. In terms of profitability, IMGN's ROE is -1.43%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, IMGN is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check MYOV's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, IMGN is priced at $31.24, while CPRX trades at $20.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas CPRX's P/E ratio is 12.26. In terms of profitability, IMGN's ROE is -1.43%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, IMGN is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check CPRX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, IMGN is priced at $31.24, while KNSA trades at $33.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas KNSA's P/E ratio is 667.60. In terms of profitability, IMGN's ROE is -1.43%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, IMGN is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check KNSA's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, RXRX has a market cap of 2.5B. Regarding current trading prices, IMGN is priced at $31.24, while RXRX trades at $5.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas RXRX's P/E ratio is -3.19. In terms of profitability, IMGN's ROE is -1.43%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, IMGN is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check RXRX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, CNTA has a market cap of 2.4B. Regarding current trading prices, IMGN is priced at $31.24, while CNTA trades at $17.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas CNTA's P/E ratio is -9.76. In terms of profitability, IMGN's ROE is -1.43%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, IMGN is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check CNTA's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, IMGN is priced at $31.24, while IBRX trades at $2.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas IBRX's P/E ratio is -5.31. In terms of profitability, IMGN's ROE is -1.43%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, IMGN is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check IBRX's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, VCYT has a market cap of 2.4B. Regarding current trading prices, IMGN is priced at $31.24, while VCYT trades at $30.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas VCYT's P/E ratio is 88.88. In terms of profitability, IMGN's ROE is -1.43%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, IMGN is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check VCYT's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, IMGN is priced at $31.24, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas PRVB's P/E ratio is -16.43. In terms of profitability, IMGN's ROE is -1.43%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, IMGN is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check PRVB's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, IMGN is priced at $31.24, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas LBPH's P/E ratio is -26.66. In terms of profitability, IMGN's ROE is -1.43%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, IMGN is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for IMGN.Check LBPH's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, TARS has a market cap of 2.3B. Regarding current trading prices, IMGN is priced at $31.24, while TARS trades at $54.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas TARS's P/E ratio is -23.67. In terms of profitability, IMGN's ROE is -1.43%, compared to TARS's ROE of -0.32%. Regarding short-term risk, IMGN is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check TARS's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, FOLD has a market cap of 2.3B. Regarding current trading prices, IMGN is priced at $31.24, while FOLD trades at $7.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas FOLD's P/E ratio is -61.67. In terms of profitability, IMGN's ROE is -1.43%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, IMGN is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check FOLD's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, IMGN is priced at $31.24, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas DICE's P/E ratio is -21.91. In terms of profitability, IMGN's ROE is -1.43%, compared to DICE's ROE of +0.56%. Regarding short-term risk, IMGN is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check DICE's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, LQDA has a market cap of 2.2B. Regarding current trading prices, IMGN is priced at $31.24, while LQDA trades at $26.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas LQDA's P/E ratio is -14.26. In terms of profitability, IMGN's ROE is -1.43%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, IMGN is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check LQDA's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, IMGN is priced at $31.24, while APGE trades at $38.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas APGE's P/E ratio is -9.01. In terms of profitability, IMGN's ROE is -1.43%, compared to APGE's ROE of -0.23%. Regarding short-term risk, IMGN is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check APGE's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, OCUL has a market cap of 2.2B. Regarding current trading prices, IMGN is priced at $31.24, while OCUL trades at $12.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas OCUL's P/E ratio is -10.02. In terms of profitability, IMGN's ROE is -1.43%, compared to OCUL's ROE of -0.70%. Regarding short-term risk, IMGN is less volatile compared to OCUL. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check OCUL's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, BLTE has a market cap of 2.2B. Regarding current trading prices, IMGN is priced at $31.24, while BLTE trades at $68.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas BLTE's P/E ratio is -42.99. In terms of profitability, IMGN's ROE is -1.43%, compared to BLTE's ROE of -0.37%. Regarding short-term risk, IMGN is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check BLTE's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, IMGN is priced at $31.24, while AGIO trades at $36.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas AGIO's P/E ratio is 3.28. In terms of profitability, IMGN's ROE is -1.43%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, IMGN is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check AGIO's competition here

IMGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMGN stands at 8.7B. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, IMGN is priced at $31.24, while DNLI trades at $14.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMGN currently has a P/E ratio of -111.55, whereas DNLI's P/E ratio is -5.23. In terms of profitability, IMGN's ROE is -1.43%, compared to DNLI's ROE of -0.41%. Regarding short-term risk, IMGN is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for IMGN.Check DNLI's competition here